ISRG Intuitive Surgical, Inc.

$369.15▲ +2.41% Healthcare Other
After hours $368.70▼ -0.12% Sep 11, 7:58 PM ET
Volume 3.35M Avg Volume (10D) 2.22M
Key Metrics & Fundamentals
Market Cap
$132.26B
P/E Ratio
42.3
Div Yield
–%
52W Range
328.57 - 603.88
% vs 50 MA
-2.20%
% vs 200 MA
-19.72%
RSI-14
48.1
MACD Histogram
-1.1100
Beta (1Y vs SPY)
0.95
Free Cash Flow
$948.40M
Gross Rev
$2.89B
Gross Profit
$1.96B
EBITDA
$1.20B
COGS
$931.90M
Operating Exp
$988.50M
Operating Income
$971.90M
EBIT
$971.90M
Pretax Income
$1.05B
Net Income
$818.10M
EPS (Diluted)
2.29
Price & Volume History
Loading chart…
Financial Overview - Income Statement Quarterly

See ISRG's money flow as a full page

AI Analysis
Generated May 20, 8:41 PM
Company Overview

Intuitive Surgical, Inc. (ISRG) is the global leader in robotic-assisted surgery, primarily known for its da Vinci surgical systems. The company designs, manufactures, and markets integrated systems that enable minimally invasive surgery, along with related instruments, accessories, and services. Its competitive position is fortified by a vast installed base, extensive intellectual property, and the significant investment required for competing platforms.

Bull Case
  • Dominant market share and established leadership in the high-growth robotic-assisted surgery market, creating substantial barriers to entry for competitors.
  • Strong recurring revenue model driven by the sale of instruments, accessories, and services tied to its large installed base of da Vinci systems.
  • Long-term growth potential fueled by an aging global population, increasing demand for minimally invasive procedures, and expansion into new surgical applications and geographies.
  • Continuous innovation and R&D investment, leading to system enhancements and new product introductions like the Ion endoluminal system, broadening its addressable market.
Bear Case
  • High valuation, with a P/E ratio of 54.7, suggesting the stock may be priced for significant future growth and potentially vulnerable to any slowdowns or market corrections.
  • Increasing competition from well-capitalized medical device companies and new entrants developing their own robotic platforms, which could erode market share or pricing power.
  • Exposure to healthcare policy changes, regulatory hurdles, and reimbursement pressures that could impact the adoption rates and profitability of its systems and procedures.
  • Potential for macroeconomic headwinds or healthcare system strains (e.g., staffing shortages, budget constraints) to delay capital equipment purchases or elective surgeries, impacting revenue growth.
Recent Performance

ISRG's stock has experienced a significant downturn, trading 25.6% below its 52-week high. It is currently below both its 50-day and 200-day moving averages by 4.7% and 11.4% respectively, indicating a bearish trend in the short to medium term. The RSI of 44.8 suggests neutral momentum, but the overall price action points to a period of consolidation or continued weakness following a substantial pullback.

AI-generated analysis is for informational purposes only and does not constitute financial advice.

Not financial advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙